Type: Public
On the web: http://www.adviral.com

In the drug business, it's not unusual for a company to toil for a dozen or more years to get a drug candidate approved and onto the market. Advanced Viral Research for the past 20 years has been working on a single drug candidate that has anti-cancer and anti-viral properties. AVR118 is in Phase II clinical trials to treat patients with advanced cancer who cannot or refuse to undergo chemotherapy. Advanced Viral Research is also researching the compound's usefulness in treating AIDS- and cancer-related wasting, rheumatoid arthritis, cancer-related conditions, and HIV and HPV (human papillomavirus). The family of former director James F. Dicke II owns nearly 20% of the company.

Officers:
Chairman and Secretary: Eli Wilner
President, CEO, and Director: Stephen M. Elliston
Acting CFO: Pharmaceuticals Manufacturers

Competitors:
Amylin Pharmaceuticals
Bristol-Myers Squibb
GlaxoSmithKline